AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) saw some unusual options trading activity on Monday. Traders acquired 6,549 call options on the stock. This represents an increase of 48% compared to the average volume of 4,417 call options.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on ABCL. Wall Street Zen downgraded shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Monday, April 20th. Cantor Fitzgerald began coverage on AbCellera Biologics in a research note on Tuesday, May 5th. They set an “overweight” rating and a $7.00 target price for the company. Finally, JonesTrading initiated coverage on AbCellera Biologics in a research report on Friday, April 10th. They issued a “buy” rating and a $11.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.80.
View Our Latest Report on ABCL
AbCellera Biologics Stock Performance
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.08. The firm had revenue of $8.32 million during the quarter, compared to analysts’ expectations of $5.41 million. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. During the same quarter last year, the company posted ($0.15) EPS. As a group, sell-side analysts predict that AbCellera Biologics will post -0.67 EPS for the current year.
Institutional Trading of AbCellera Biologics
A number of large investors have recently modified their holdings of ABCL. AssuredPartners Investment Advisors LLC purchased a new stake in shares of AbCellera Biologics during the 4th quarter worth $34,000. OneDigital Investment Advisors LLC acquired a new stake in shares of AbCellera Biologics during the 3rd quarter worth about $52,000. Insigneo Advisory Services LLC purchased a new stake in AbCellera Biologics during the third quarter worth approximately $52,000. Voleon Capital Management LP purchased a new stake in AbCellera Biologics during the third quarter worth approximately $56,000. Finally, Engineers Gate Manager LP acquired a new position in AbCellera Biologics in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 61.42% of the company’s stock.
About AbCellera Biologics
AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.
AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.
Featured Stories
- Five stocks we like better than AbCellera Biologics
- Nebius Is Up Nearly 175% This Year—Here’s What’s Driving the Latest Run
- Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look
- 3 Energy Stocks Built for the AI Power Boom—And Beyond
- Allstate’s Comeback Is Turning Into a Profit Machine
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
